Kimi Iguchi Sage Therapeutics, Inc. (SAGE) insider trading activity

Kimi Iguchi is CFO & Treasurer of Sage Therapeutics, Inc.. Currently has a direct ownership of 81,405 shares of SAGE, which is worth approximately $494,942. The most recent transaction as insider was on Aug 05, 2024, when has been sold 3,636 shares (Common Stock) at a price of $8.96 per share, resulting in proceeds of $32,578. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 81.4K

0.34% 3M change

24.17% 12M change

Total Value Held $494,942

KIMI IGUCHI Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 05 2024	SELL Payment of exercise price or tax liability	$32,578 $8.96 p/Share	3,636 Reduced 4.28%	81,405 Common Stock
Aug 05 2024	BUY Grant, award, or other acquisition	-	13,500 Added 13.7%	85,041 Common Stock
Feb 13 2024	BUY Grant, award, or other acquisition	-	11,250 Added 12.11%	81,679 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	$2,233 $1.36 p/Share	1,642 Added 2.28%	70,429 Common Stock
Nov 28 2023	SELL Payment of exercise price or tax liability	$18,171 $19.27 p/Share	943 Reduced 1.35%	68,787 Common Stock
Nov 28 2023	BUY Grant, award, or other acquisition	-	3,500 Added 4.78%	69,730 Common Stock
Mar 15 2023	BUY Exercise of conversion of derivative security	$4,080 $1.36 p/Share	3,000 Added 4.38%	65,560 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	$340 $1.36 p/Share	250 Added 0.4%	62,560 Common Stock
Feb 21 2023	BUY Exercise of conversion of derivative security	$1,020 $1.36 p/Share	750 Added 1.19%	62,310 Common Stock
Feb 03 2023	SELL Payment of exercise price or tax liability	$40,362 $44.16 p/Share	914 Reduced 1.46%	61,560 Common Stock
Feb 03 2023	BUY Grant, award, or other acquisition	-	2,850 Added 4.36%	62,474 Common Stock
Jan 09 2023	BUY Exercise of conversion of derivative security	$2,176 $1.36 p/Share	1,600 Added 2.61%	59,624 Common Stock
Jan 04 2023	BUY Exercise of conversion of derivative security	$2,448 $1.36 p/Share	1,800 Added 3.01%	58,024 Common Stock
Feb 17 2022	BUY Exercise of conversion of derivative security	$6,120 $1.36 p/Share	4,500 Added 7.49%	55,600 Common Stock
Nov 23 2021	BUY Exercise of conversion of derivative security	$1,360 $1.36 p/Share	1,000 Added 1.92%	51,100 Common Stock
Nov 22 2021	BUY Exercise of conversion of derivative security	$3,400 $1.36 p/Share	2,500 Added 4.75%	50,100 Common Stock
Oct 19 2021	SELL Payment of exercise price or tax liability	$41,257 $40.29 p/Share	1,024 Reduced 2.11%	47,600 Common Stock
Oct 19 2021	BUY Grant, award, or other acquisition	-	3,800 Added 7.25%	48,624 Common Stock
Jun 16 2021	BUY Exercise of conversion of derivative security	$2,720 $1.36 p/Share	2,000 Added 4.3%	44,533 Common Stock
Jun 15 2021	SELL Payment of exercise price or tax liability	$48,334 $58.8 p/Share	822 Reduced 1.9%	42,533 Common Stock
Jun 15 2021	BUY Grant, award, or other acquisition	-	3,500 Added 7.47%	43,355 Common Stock
Jun 15 2021	BUY Exercise of conversion of derivative security	$4,080 $1.36 p/Share	3,000 Added 7.0%	39,855 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	$2,040 $1.36 p/Share	1,500 Added 3.91%	36,855 Common Stock
Jan 05 2021	BUY Exercise of conversion of derivative security	$2,380 $1.36 p/Share	1,750 Added 4.72%	35,355 Common Stock

Kimi Iguchi

CFO & Treasurer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SAGE shares.

Notify only if

Value

Insider Trading

Get notified when an Sage Therapeutics, Inc. insider buys or sells SAGE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sage Therapeutics, Inc.

Track Activities on SAGE

Account